Thalia Therapeutics (LON:THAT – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported GBX (0.09) earnings per share (EPS) for the quarter, Digital Look Earnings reports.
Thalia Therapeutics Stock Down 1.6%
Shares of LON:THAT opened at GBX 0.61 on Thursday. Thalia Therapeutics has a fifty-two week low of GBX 0.40 and a fifty-two week high of GBX 0.95. The stock has a market capitalization of £10.92 million and a price-to-earnings ratio of -3.62.
Thalia Therapeutics Company Profile
RNA therapeutics is one of the most rapidly growing therapeutic sectors that is set to impact the treatment of a wide range of diseases. Thalia Therapeutics is developing a wholly owned pipeline of novel RNA therapeutics for cardiovascular and other diseases, as well as developing Nuvec®, its proprietary gene delivery system, to further differentiate its therapeutic assets.
Featured Articles
- Five stocks we like better than Thalia Therapeutics
- Cleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket Reach
- L3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock
- Boeing’s Fighter Victory Opens the Door to Decades of Defense Revenue
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
Receive News & Ratings for Thalia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thalia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
